[Refractory/relapsed hemophagocytic lymphohistiocytosis treated with ruxolitinib: three cases report and literatures review].
作者信息
Wang J S, Wang Y N, Wu L, Lai W Y, Wang Z
机构信息
Department of Hematology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China.
出版信息
Zhonghua Xue Ye Xue Za Zhi. 2019 Jan 14;40(1):73-75. doi: 10.3760/cma.j.issn.0253-2727.2019.01.014.
Abstract
摘要
相似文献
1
[Refractory/relapsed hemophagocytic lymphohistiocytosis treated with ruxolitinib: three cases report and literatures review].[芦可替尼治疗难治性/复发性噬血细胞性淋巴组织细胞增生症：三例报告及文献复习]
Zhonghua Xue Ye Xue Za Zhi. 2019 Jan 14;40(1):73-75. doi: 10.3760/cma.j.issn.0253-2727.2019.01.014.
2
Ruxolitinib for refractory/relapsed hemophagocytic lymphohistiocytosis.芦可替尼用于难治性/复发性噬血细胞性淋巴组织细胞增生症
Haematologica. 2020 May;105(5):e210-e212. doi: 10.3324/haematol.2019.222471. Epub 2019 Sep 12.
3
Hemophagocytic lymphohistiocytosis responding to withdrawal of gluten: a case report.对麸质戒断有反应的噬血细胞性淋巴组织细胞增生症：一例报告
J Med Case Rep. 2016 Sep 22;10(1):262. doi: 10.1186/s13256-016-1049-6.
4
Hemophagocytic lymphohistiocytosis in very young infants.极低龄婴儿的噬血细胞性淋巴组织细胞增生症
Pediatr Blood Cancer. 2009 Jan;52(1):137-9. doi: 10.1002/pbc.21758.
5
Elevation of CD16CD56 NK-cells and down-regulation of serum interleukin-21 (IL-21) and IL-1α after splenectomy in relapsed hemophagocytic lymphohistiocytosis of unknown cause.不明原因复发性噬血细胞性淋巴组织细胞增生症患者脾切除术后CD16CD56自然杀伤细胞升高及血清白细胞介素-21（IL-21）和IL-1α下调
Hematology. 2017 Sep;22(8):477-483. doi: 10.1080/10245332.2017.1311443. Epub 2017 Apr 15.
6
Immunotherapy of familial hemophagocytic lymphohistiocytosis with antithymocyte globulins: a single-center retrospective report of 38 patients.用抗胸腺细胞球蛋白治疗家族性噬血细胞性淋巴组织细胞增生症：38例患者的单中心回顾性报告
Pediatrics. 2007 Sep;120(3):e622-8. doi: 10.1542/peds.2006-3164. Epub 2007 Aug 14.
7
Successful rituximab treatment of refractory hemophagocytic lymphohistiocytosis and autoimmune hemolytic anemia associated with systemic lupus erythematosus.利妥昔单抗成功治疗与系统性红斑狼疮相关的难治性噬血细胞性淋巴组织细胞增生症和自身免疫性溶血性贫血。
Mod Rheumatol. 2014 Sep;24(5):855-7. doi: 10.3109/14397595.2013.874740. Epub 2014 Feb 11.
8
Hemophagocytic lymphohistiocytosis after lung transplant: report of 2 cases and a literature review.肺移植术后噬血细胞性淋巴组织细胞增生症：2例报告及文献复习
Exp Clin Transplant. 2011 Jun;9(3):217-22.
9
High-Volume Hemofiltration in Critically Ill Patients With Secondary Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome: A Prospective Study in the PICU.重症监护病房中继发性噬血细胞性淋巴组织细胞增生症/巨噬细胞活化综合征危重症患者的高容量血液滤过：一项前瞻性研究
Pediatr Crit Care Med. 2016 Oct;17(10):e437-e443. doi: 10.1097/PCC.0000000000000896.
10
Rituximab, etoposide, methylprednisolone, high-dose cytarabine, and cisplatin in the treatment of secondary hemophagocytic lymphohistiocytosis with classical Hodgkin lymphoma: a case report and review of the literature.利妥昔单抗、依托泊苷、甲泼尼龙、大剂量阿糖胞苷和顺铂治疗伴经典型霍奇金淋巴瘤的继发性噬血细胞性淋巴组织细胞增生症：1例报告并文献复习
J Med Case Rep. 2016 Dec 20;10(1):365. doi: 10.1186/s13256-016-1143-9.
引用本文的文献
1
Ruxolitinib combined with doxorubicin, etoposide, and dexamethasone for the treatment of the lymphoma-associated hemophagocytic syndrome.芦可替尼联合多柔比星、依托泊苷和地塞米松治疗淋巴瘤相关噬血细胞综合征。
J Cancer Res Clin Oncol. 2020 Nov;146(11):3063-3074. doi: 10.1007/s00432-020-03301-y. Epub 2020 Jul 2.
2
Efficacy of ruxolitinib in subcutaneous panniculitis-like T-cell lymphoma and hemophagocytic lymphohistiocytosis.芦可替尼治疗皮下脂膜炎样T细胞淋巴瘤和噬血细胞性淋巴组织细胞增生症的疗效。
Blood Adv. 2020 Apr 14;4(7):1383-1387. doi: 10.1182/bloodadvances.2020001497.
3
Challenges in the diagnosis of hemophagocytic lymphohistiocytosis: Recommendations from the North American Consortium for Histiocytosis (NACHO).噬血细胞性淋巴组织细胞增生症诊断中的挑战：北美组织细胞增生症联盟（NACHO）的建议。
Pediatr Blood Cancer. 2019 Nov;66(11):e27929. doi: 10.1002/pbc.27929. Epub 2019 Jul 24.
本文引用的文献
1
Ruxolitinib for treatment of refractory hemophagocytic lymphohistiocytosis.芦可替尼用于治疗难治性噬血细胞性淋巴组织细胞增生症。
Blood Adv. 2017 Aug 17;1(19):1533-1536. doi: 10.1182/bloodadvances.2017007526. eCollection 2017 Aug 22.
2
Ruxolitinib for secondary hemophagocytic lymphohistiocytosis: First case report.芦可替尼治疗继发性噬血细胞性淋巴组织细胞增生症：首例病例报告。
Hematol Oncol Stem Cell Ther. 2019 Sep;12(3):166-170. doi: 10.1016/j.hemonc.2017.07.002. Epub 2017 Aug 16.
3
Therapeutic effect of JAK1/2 blockade on the manifestations of hemophagocytic lymphohistiocytosis in mice.JAK1/2 阻断对小鼠噬血细胞性淋巴组织细胞增生症表现的治疗作用。
Blood. 2016 Jul 7;128(1):60-71. doi: 10.1182/blood-2016-02-700013. Epub 2016 May 24.
4
Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis.在噬血细胞性淋巴组织细胞增生症的小鼠模型中，抑制Janus激酶可减轻炎症并改善疾病。
Blood. 2016 Mar 31;127(13):1666-75. doi: 10.1182/blood-2015-12-684399. Epub 2016 Jan 29.
5
Multicenter study of combination DEP regimen as a salvage therapy for adult refractory hemophagocytic lymphohistiocytosis.多中心研究联合DEP方案作为成人难治性噬血细胞性淋巴组织细胞增生症的挽救治疗方法
Blood. 2015 Nov 5;126(19):2186-92. doi: 10.1182/blood-2015-05-644914. Epub 2015 Aug 19.
6
Hemophagocytic lymphohistiocytosis (HLH): A heterogeneous spectrum of cytokine-driven immune disorders.噬血细胞性淋巴组织细胞增生症（HLH）：一种由细胞因子驱动的免疫紊乱的异质性谱。
Cytokine Growth Factor Rev. 2015 Jun;26(3):263-80. doi: 10.1016/j.cytogfr.2014.10.001. Epub 2014 Oct 28.
7
Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition.斑秃由细胞毒性 T 淋巴细胞驱动，并可被 JAK 抑制逆转。
Nat Med. 2014 Sep;20(9):1043-9. doi: 10.1038/nm.3645. Epub 2014 Aug 17.
8
Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy.blinatumomab 治疗后细胞因子释放综合征与异常巨噬细胞活化有关，并通过细胞因子导向治疗得到改善。
Blood. 2013 Jun 27;121(26):5154-7. doi: 10.1182/blood-2013-02-485623. Epub 2013 May 15.
9
Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab.用阿仑单抗对难治性噬血细胞性淋巴组织细胞增生症进行挽救性治疗。
Pediatr Blood Cancer. 2013 Jan;60(1):101-9. doi: 10.1002/pbc.24188. Epub 2012 Apr 22.
10
JAK and STAT signaling molecules in immunoregulation and immune-mediated disease.JAK 和 STAT 信号分子在免疫调节和免疫介导的疾病中的作用。
Immunity. 2012 Apr 20;36(4):542-50. doi: 10.1016/j.immuni.2012.03.014.
Zotero 插件